R

Roquefort Therapeutics PLC
LSE:ROQ

Watchlist Manager
Roquefort Therapeutics PLC
LSE:ROQ
Watchlist
Price: 1.18 GBX -9.23% Market Closed
Market Cap: £1.9m

Operating Margin

0%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
£0
/
£0

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
GBX0
/
£0

Peer Comparison

Country Company Market Cap Operating
Margin
UK
Roquefort Therapeutics PLC
LSE:ROQ
1.9m GBP
Loading...
US
SoFi Technologies Inc
NASDAQ:SOFI
29.5B USD
Loading...
MC
HAL Trust
AEX:HAL
14B EUR
Loading...
US
Annaly Capital Management Inc
NYSE:NLY
16.3B USD
Loading...
US
WP Carey Inc
NYSE:WPC
15.1B USD
Loading...
US
Ares Capital Corp
NASDAQ:ARCC
14.5B USD
Loading...
US
AltC Acquisition Corp
NYSE:OKLO
13.5B USD
Loading...
BE
Sofina SA
XBRU:SOF
9.1B EUR
Loading...
US
Starwood Property Trust Inc
NYSE:STWD
6.7B USD
Loading...
US
Main Street Capital Corp
NYSE:MAIN
5.8B USD
Loading...
KY
JATT Acquisition Corp
F:1GU
4.6B EUR
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

Roquefort Therapeutics PLC
Glance View

Market Cap
1.9m GBX
Industry
N/A

Roquefort Therapeutics plc operates as an investment company. The firm is developing products through the pre-clinical phase. The firm operates through its subsidiary Lyramid Pty Ltd (Lyramid). Lyramid is a pre-clinical biotechnology company focused on developing first-in-class Midkine inhibiting ribonucleic acid (RNA) therapeutic drugs for the treatment of cancer, chronic inflammatory, and autoimmune disorders, as well as lung diseases such as COVID-19. Lyramid has identified the therapeutic potential of Midkine for a number of clinical indications of unmet needs. Lyramid also intends to develop its oligonucleotide, and potentially antibody, drugs through preclinical and early clinical development.

ROQ Intrinsic Value
0.19 GBX
Overvaluation 84%
Intrinsic Value
Price
R
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Back to Top